Mice bearing USP14-deficient tumors responded more robustly to oxaliplatin, with a substantial reduction in both tumor size and weight by approximately 32% and 67% (oxaliplatin treatment), as compared to control tumors (Figs. 2f–h and S2d). The gene discussed is USP14; the disease is neoplasm.